| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/22/2009 | WO2009063222A2 Solid compositions |
| 05/22/2009 | WO2009063221A2 Methods of treating or preventing inflammatory diseases of the intestinal tract |
| 05/22/2009 | WO2009063215A2 Use of crth2 antagonist compounds |
| 05/22/2009 | WO2009063202A2 Use of crth2 antagonist compounds |
| 05/22/2009 | WO2009063171A1 Novel rotigotine salts |
| 05/22/2009 | WO2009063170A1 Preparation of crystalline rotigotine base |
| 05/22/2009 | WO2009063081A2 Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc. |
| 05/22/2009 | WO2009063070A2 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 05/22/2009 | WO2009063061A2 Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
| 05/22/2009 | WO2009063054A1 Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| 05/22/2009 | WO2009063044A1 Treatment of parasite diseases using vitamin k3 |
| 05/22/2009 | WO2009063029A2 Substituted amides, manufacturing and use thereof as medicaments |
| 05/22/2009 | WO2009063028A2 Substituted amides, manufacturing and use thereof as medicaments |
| 05/22/2009 | WO2009063021A1 Pharmaceutical forms for the release of active compounds |
| 05/22/2009 | WO2009063018A1 Aqueous iron dextran preparation having one or more para-hydroxybenzoate compounds and/or salts thereof |
| 05/22/2009 | WO2009062990A2 Equilibrative nucleoside transporter ent1 inhibitors |
| 05/22/2009 | WO2009062989A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use |
| 05/22/2009 | WO2009062987A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use |
| 05/22/2009 | WO2009062964A1 Novel solvate |
| 05/22/2009 | WO2009062963A1 Crystalline forms of tigecycline hydrochloride |
| 05/22/2009 | WO2009062950A1 Novel compounds |
| 05/22/2009 | WO2009062949A1 New polymorphic forms of n-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide |
| 05/22/2009 | WO2009062939A1 Anthelmintic paste comprising praziquantel, a macrolide lactone, cyclodextrin and a thickener |
| 05/22/2009 | WO2009062932A1 Condensation products based on bicyclic or polycyclic aromatic or heteroaromatic compounds |
| 05/22/2009 | WO2009062930A1 Heterocyclic derivatives |
| 05/22/2009 | WO2009062914A2 Blood pressure lowering combination comprising ipp and/or vpp |
| 05/22/2009 | WO2009062910A1 Composition for moderating triglyceride and cholesterol levels |
| 05/22/2009 | WO2009062883A1 Drug active in neuropathic pain |
| 05/22/2009 | WO2009062874A2 Benzimidazole derivatives and their use as fxr agonists |
| 05/22/2009 | WO2009062746A2 Topical drugs for use in antifungal therapy |
| 05/22/2009 | WO2009062740A1 Use of an ozone/oxygen mixture as primary anticancer therapy through intraperitoneal insufflation |
| 05/22/2009 | WO2009062737A1 Silibinin component for the treatment of hepatitis |
| 05/22/2009 | WO2009062690A1 Axl antibodies |
| 05/22/2009 | WO2009062683A1 C-19 steroids for therapeutic uses |
| 05/22/2009 | WO2009062682A1 C-19 steroids for cosmetic and further uses |
| 05/22/2009 | WO2009062662A1 Pharmaceutical and nutraceutical compositions based on menaquinols |
| 05/22/2009 | WO2009062658A1 Methods for identification of jak kinase interacting molecules and for the purification of jak kinases |
| 05/22/2009 | WO2009062619A1 New crystalline diphenyl acetidinone hydrate, pharmaceutical agent containing said compound and use thereof |
| 05/22/2009 | WO2009062605A1 Trisubstituted furopyrimidines and the use thereof as activators of the ip receptor |
| 05/22/2009 | WO2009062576A2 Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same |
| 05/22/2009 | WO2009062517A1 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity |
| 05/22/2009 | WO2009062431A1 A method for smoking cessation |
| 05/22/2009 | WO2009062402A1 Quinazolinone derivatives, the preparation methods and uses thereof |
| 05/22/2009 | WO2009062398A1 Novel thermosensitive liposomes containing therapeutic agents |
| 05/22/2009 | WO2009062391A1 Memantine protects inflammation-related degeneration of dopamine neurons through inhibition of over-activated microglia and release of neurotrophic factors from astroglia |
| 05/22/2009 | WO2009062374A1 The pharmaceutical use of liquiritigenin for preparing medicine for treating neurodegenerative diseases |
| 05/22/2009 | WO2009062371A1 Carbamate derivatives, and the use as medicament |
| 05/22/2009 | WO2009062342A1 Cephalomannine derivatives and their preparation, medicinal composition and use |
| 05/22/2009 | WO2009062319A1 Indole compounds and methods for treating visceral pain |
| 05/22/2009 | WO2009062318A1 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity |
| 05/22/2009 | WO2009062313A1 Composition containing granulocyte colony stimulating factor (gcsf) for hair growth |
| 05/22/2009 | WO2009062309A1 Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof |
| 05/22/2009 | WO2009062308A1 Inhibitors of human immunodeficiency virus replication |
| 05/22/2009 | WO2009062289A1 Inhibitors of human immunodeficiency virus replication |
| 05/22/2009 | WO2009062288A1 Inhibitors of human immunodeficiency virus replication |
| 05/22/2009 | WO2009062285A1 Inhibitors of human immunodeficiency virus replication |
| 05/22/2009 | WO2009062258A1 N-containing heterocyclic compounds |
| 05/22/2009 | WO2009047754A3 Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation |
| 05/22/2009 | WO2009046314A3 Moenomycin analogs, methods of synthesis, and uses thereof |
| 05/22/2009 | WO2009045965A3 Stat5a and its functional tumor suppressor analogs for treatment of malignancies expressing npm/alk and other oncogenic kinases |
| 05/22/2009 | WO2009045900A3 Methods for treating or preventing diseases associated with low bone mass |
| 05/22/2009 | WO2009045054A3 A composition for treatment of conjunctivitis comprising chlorogenic acid and derivatives thereof |
| 05/22/2009 | WO2009045053A3 A cancer sensitizer comprising chlorogenic acid |
| 05/22/2009 | WO2009044294A3 Means and methods for the treatment of cataract and presbyopia |
| 05/22/2009 | WO2009040755A3 Pyrrole compounds as inhibitors of mycobacteria, synthesis thereof ans intermediates thereto |
| 05/22/2009 | WO2009040552A3 Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof |
| 05/22/2009 | WO2009039397A3 Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer |
| 05/22/2009 | WO2009037542A3 Spirocyclic compounds as stearoyl coa desaturase inhibitors |
| 05/22/2009 | WO2009036428A3 1,3,4-trisubstituted benzenes |
| 05/22/2009 | WO2009035929A3 Cardiovascular and brain cell therapy using intracellular ryanodine receptor modulation by the estrogen receptor beta |
| 05/22/2009 | WO2009035253A3 Novel use of scoparone |
| 05/22/2009 | WO2009034464A3 Indole related compounds with physiological activity |
| 05/22/2009 | WO2009034458A3 Oxygen permeable polymeric nanocontainers for encapsulation of sensitive compounds |
| 05/22/2009 | WO2009034432A3 Novel compounds active as muscarinic receptor antagonists |
| 05/22/2009 | WO2009034028A3 Novel compounds |
| 05/22/2009 | WO2009032870A3 Method to ameliorate oxidative stress and improve working memory via pterostilbene administration |
| 05/22/2009 | WO2009032321A3 A method for treating diabetes |
| 05/22/2009 | WO2009027956A3 Syndrome x composition and method of lowering blood pressure and glycemic index |
| 05/22/2009 | WO2009027852A3 Methods and compositions for treating gastrointestinal conditions |
| 05/22/2009 | WO2009026574A3 Immunogenic compositions and uses thereof |
| 05/22/2009 | WO2009026166A3 Antiinfective flavonol compounds and methods of use thereof |
| 05/22/2009 | WO2009025820A3 Rationally improved isoniazid and ethionamide derivatives and activity through selective isotopic substitution |
| 05/22/2009 | WO2009024820A3 Therapeutic treatment 014 |
| 05/22/2009 | WO2009024542A3 Purin derivatives for use in the treatment of fab-related diseases |
| 05/22/2009 | WO2009023620A3 Compositions with perfluorinated ingredients |
| 05/22/2009 | WO2009019505A3 Drug combinations for the treatment of duchenne muscular dystrophy |
| 05/22/2009 | WO2009017874A3 Novel curcumin derivatives and their pharmaceutical uses thereof |
| 05/22/2009 | WO2009016629A3 Pharmaceutical composition for treating wounds and related methods |
| 05/22/2009 | WO2009016072A3 A morpholinyl anthracycline derivative combined with protein kinase inhibitors |
| 05/22/2009 | WO2009015366A3 Use of thyroid hormone conversion inhibitors to treat hyperproliferative disorders |
| 05/22/2009 | WO2009007622A3 Dermatological composition containing calcitriol lipidic vesicles, method for preparing same and use thereof |
| 05/22/2009 | WO2008157103A3 Modified release solid or semi-solid dosage forms |
| 05/22/2009 | WO2008138968A3 Dosage form comprising 10-[(3s)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine, provided in a form suitable for oral administration of a daily dose of 1 mg to 3 mg |
| 05/22/2009 | WO2008136815A3 5, 6-ring annulated indole derivatives and use thereof |
| 05/22/2009 | WO2008135671A3 Derivatives of the aminated hydroxyquinoline class for treating cancers |
| 05/22/2009 | WO2008125989A3 Polyketide based proteasome inhibitor |
| 05/22/2009 | WO2008118403A3 Method of using a pkc inhibitor to reverse prefrontal cortical declines |
| 05/22/2009 | WO2008100450A3 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| 05/22/2009 | WO2008100449A3 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| 05/22/2009 | WO2008098168A3 High-dose, long-acting ectoparasiticide for extended control |